The NOGO receptor NgR2, a novel aV?3 integrin effector, induces neuroendocrine differentiation in prostate cancer.

Quaglia F, Krishn SR, Sossey-Alaoui K, Rana PS, Pluskota E, Park PH, Shields CD, Lin S, McCue P, Kossenkov AV, Wang Y, Goodrich DW, Ku SY, Beltran H, Kelly WK, Corey E, Klose M, Bandtlow C, Liu Q, Altieri DC, Plow EF, Languino LR. The NOGO receptor NgR2, a novel aV?3 integrin effector, induces neuroendocrine differentiation in prostate cancer. Sci Rep. 2022 11 07; 12(1):18879.

View in: PubMed